Cytosorbents Crp (CTSO)
Healthcare
Medical Devices
0.36 $
+3.1%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Cytosorbents Crp (CTSO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 85.8% of the shares are freely tradable; institutional investors hold 26.4%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
26.4%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
15.3%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
85.8%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
3.6%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
63Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Avenir Corporation | 8.31 | 5,215,776 | -0.3 | 03/31/2026 |
| Vanguard Group Inc | 3.51 | 2,204,294 | +0.0 | 12/31/2025 |
| Vanguard Capital Management, LLC | 2.99 | 1,879,989 | +0.0 | 03/31/2026 |
| Skylands Capital, LLC | 2.72 | 1,707,498 | -7.9 | 03/31/2026 |
| Neuberger Berman Group LLC | 2.68 | 1,683,007 | +3.5 | 03/31/2026 |
| CM Management, LLC | 2.35 | 1,476,500 | +0.0 | 03/31/2026 |
| BlackRock Inc | 1.25 | 782,992 | +1.6 | 03/31/2026 |
| Geode Capital Management, LLC | 1.13 | 707,262 | +17.1 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.03 | 1,274,363 | +0.0 | 04/30/2026 |
| Neuberger Intrinsic Value I | 1.03 | 647,006 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.